Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197012 · ClinicalTrials.gov registry record · Early Phase 1
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
A Early Phase 1 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03197012 is a Early Phase 1 study that has completed, run by Thomas Hope. The registered enrollment target is 10 participants.
The verdict
NCT03197012, a Early Phase 1 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery. Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.
Interventions
- DRUG 90Y-DOTA-TOC
- DRUG 68Ga-DOTA-TOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197012
The ClinicalTrials.gov registry entry for NCT03197012 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 90Y-DOTA-TOC is the first listed.
NCT03197012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03197012 about?
NCT03197012 is a clinical study titled "Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor". This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery. Participants in th...
What is the current status of trial NCT03197012?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2017-07-01. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT03197012?
The interventions under investigation include: 90Y-DOTA-TOC (DRUG), 68Ga-DOTA-TOC (DRUG).
Who is sponsoring clinical trial NCT03197012?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.